Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 18/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 18/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6925333 | 0.83 | CYP11B1 (0.64) | CYP11B1CYP11B2CYP19A1IDO1FNTA | |
| SCHEMBL27984850 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2IDO1 | |
| Hydrochloric Acid SCHEMBL17185367 | 0.80 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8865733 | 0.78 | CYP11B1 (0.62) | CYP11B1CYP11B2 | |
| SCHEMBL3826717 | 0.78 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1FNTAPGGT1B | |
| SCHEMBL31471987 | 0.77 | CYP11B1 (0.62) | CYP11B1CYP11B2FNTAPGGT1B | |
| SCHEMBL28174123 | 0.77 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP19A1IDO1 | |
| SCHEMBL17544564 | 0.76 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP19A1IDO1 | |
| SCHEMBL32683807 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP19A1IDO1 | |
| SCHEMBL17544474 | 0.75 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP19A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802941-B2 | Compounds and methods for inhibiting histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| CN-107074807-A | Compositions and methods for inhibiting histone demethylase | 吉利德科学公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-3186238-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS | 2016-04-14 | — | — | US | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033169-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102096-A1 | COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES | PHF8, KDM3A, PHF2 | CYP11B1 2207/4885CYP11B2 3002/4885CYP19A1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.